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Aims ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1motif, member 13, is a metalloprotease
that cleaves von Willebrand factor (VWF). There is considerable evidence that VWF levels increase and ADAMTS13
levels decrease in ST-elevation myocardial infarction (STEMI) patients. It is unclear whether this contributes to no re-
flow, infarct size, and intramyocardial haemorrhage (IMH). We aimed to determine the role of ADAMTS13 in STEMI




In 49 consecutive percutaneous coronary intervention (PCI)-treated STEMI patients, blood samples were collected dir-
ectly after through 7 days following PCI. Cardiac magnetic resonance was performed 4–6 days after PCI to determine
infarct size and IMH. In 23 Yorkshire swine, the circumflex coronary artery was occluded for 75 min. rADAMTS13 or
vehicle was administered intracoronary following reperfusion. Myocardial injury and infarct characteristics were as-
sessed using cardiac enzymes, ECG, and histopathology. In patients with IMH, VWF activity and VWF antigen were sig-
nificantly elevated directly after PCI and for all subsequent measurements, and ADAMTS13 activity significantly
decreased at 4 and 7 days following PCI, in comparison with patients without IMH. VWF activity and ADAMTS13 ac-
tivity were not related to infarct size. In rADAMTS13-treated animals, no differences in infarct size, IMH, or formation
of microthrombi were witnessed compared with controls.
Conclusions No correlation was found between VWF/ADAMTS13 and infarct size in patients. However, patients suffering from IMH
had significantly higher VWF activity and lower ADAMTS13 activity. Intracoronary administration of rADAMTS13 did
not decrease infarct size or IMH in a porcine model of myocardial ischaemia-reperfusion. These data dispute the im-
balance in ADAMTS13 and VWF as the cause of no reflow.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords von Willebrand factor † ADAMTS13 † Acute myocardial infarction † Ischemia-reperfusion injury † No reflow
1. Introduction
In up to 40% of ST-elevation myocardial infarction (STEMI) patients,
imperfections in myocardial blood flow are observed despite
reperfusion at the epicardial level.1 This phenomenon, also referred
to as no reflow, is occasionally observed angiographically directly after
percutaneous coronary intervention (PCI). In a majority of cases, it is
established several days later by cardiac magnetic resonance (CMR)
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as a hypoenhanced area within the hyperenhanced infarcted myocar-
dium.2,3 Both angiographic no reflow and CMR-defined no reflow are
related to increased cardiac failure and death.4–6 Various mechanisms
for this phenomenon have been proposed including tissue oedema, dis-
tal embolization of atherosclerotic debris, and also local microthrombi
causing occlusion of capillaries leading to larger infarct size and worse
outcome.7 Recently, it was shown that CMR-defined no reflow actually
contains intramyocardial haemorrhage (IMH) and complete micro-
vascular destruction.8–10
von Willebrand factor (VWF) is an important factor in primary
haemostasis. It attracts platelets to damaged endothelium, causing
platelet adhesion; and it thereby initiates and stabilizes platelet aggrega-
tion. VWF is released from endothelium during vessel injury in the form
of ultra-large VWF multimers, which contain several platelet binding
sites and are therefore more prothrombotic. ADAMTS13, a disintegrin
and metalloprotease with a thrombospondin type 1 repeats-13, is a
metalloprotease that cleaves VWF, reducing the size of VWF multi-
mers and diminishing their prothrombotic features.11 In STEMI pa-
tients, VWF levels are increased,12,13 but it is not known whether
this is related to infarct size and occurrence of no reflow and IMH.
In parallel with the increase in VWF, ADAMTS13 decreases in STEMI
patients.12,13 Recently, it was shown that ADAMTS13 knockout mice
developed larger myocardial infarctions after coronary occlusion and
showed decreased left ventricular function when compared with
wild-type mice. Also, treatment with recombinant ADAMTS13
(rADAMTS13) reduced infarct size in wild-type mice.14–16 However,
the potential beneficial effects of rADAMTS13 on infarct size and in-
farct characteristics have never been tested in a large animal model
of myocardial ischaemia-reperfusion.
In the present study, the relationship between ADAMTS13 and VWF
levels and CMR-derived infarct size as well as occurrence of IMH was
determined prospectively in STEMI patients. Also, in a porcine model of
myocardial ischaemia-reperfusion, closely resembling the clinical scen-
ario of acute myocardial infarction (AMI) treated with primary PCI,
intracoronary infusion of rADAMTS13 was tested for its effects on
infarct size, formation of microthrombi, and IMH.
2. Methods
2.1 Patient study
Sixty consecutive patients with acute STEMI, presenting at the catheteriza-
tion laboratory within 6 h after onset of symptoms and successfully treated
by primary PCI, were included in a prospective study as reported earlier.17
For the present analysis, only patients who underwent CMR at Days 4–6
after PCI were selected (n ¼ 49). The study was conducted in accordance
with the Declaration of Helsinki and the protocol was approved by the eth-
ics committee of the VU University Medical Center. Upon arrival, daily ad-
ministration of 100 mg acetylsalicylic acid and 10 mg prasugrel was started.
Bivalirudin was administered as a single bolus, followed by 0.25 mg/kg intra-
venously during 4 h. Bloodwaswithdrawn directly after (T0) and at 1, 4, and
7 days (T1, T4, and T7) after PCI. VWF activity, VWF antigen, VWF propep-
tide, ADAMTS13 activity, fibrinogen, and D-dimer were measured. Further
details on methods such as exclusion criteria and measurement of
ST-resolution can be found in the Supplementary material online.
2.2 Cardiovascular magnetic resonance
imaging
CMR was performed between 4 and 6 days after PCI using a 1.5 Tesla
MR-scanner (Avanto, Siemens, Erlangen, Germany). IMH was identified
on T2w-images as hypointense areas within the hyperintense signal of
infarct-related oedema. Cine images were analysed by tracing the endocar-
dial and epicardial myocardial borders in both end-diastolic and
end-systolic phases, providing myocardial volumes and ejection fraction.
Quantification of infarct size was performed on short-axis late
gadolinium-enhanced images. Further details on acquisition and analysis
and definitions of CMR parameters are specified in the Supplementary
material online.
2.3 Porcine ischaemia-reperfusion model
Approval was obtained from the local Animal Ethics Committee of the VU
University Medical Center. The animal procedures that were performed
conform the guidelines from Directive 2010/63/EU of the European Parlia-
ment on the protection of animals used for scientific purposes. A full de-
scription of animal experimental procedures, including continuous
12-lead electrocardiograms and transthoracic echocardiography, can be
found in the Supplementary material online. See also Figure 4A for the study
flow chart. In brief, 23 female Yorkshire swine were included; 12 animals
received vehicle and 11 were given rADAMTS13. An over-the-wire balloon
was placed in the proximal left circumflex artery and inflated for 75 min.
During coronary occlusion, animals received a bolus of 5000 IU of unfrac-
tionated heparin and the same amount after deflation of the balloon.
After reperfusion, 300 mg acetylsalicylic acid and 300 mg clopidogrel
were administered. All animals were given daily doses of 80 mg acetylsali-
cylic acid and 75 mg clopidogrel until their planned sacrifice 7 days after
ischaemia-reperfusion. rADAMTS13 (400 U/kg body weight ¼ 320 mL/kg
body weight, Baxter Innovations, Vienna, Austria) or a comparable amount
of vehicle were administered intracoronary in one single bolus 15 min after
reperfusion by an investigator blinded for treatment.
2.4 Histopathological analysis
Detailed information on histopathological methods can be found in the
Supplementary material online. In brief, on the seventh day after experi-
mental AMI, animals were sedated and killed. Total infarct size and IMH
were determined macroscopically and microscopically (Figure 4C).
Anti-CD31 staining was performed to detect (micro-)thrombi and (micro-)
vessels. For both treatment arms, microthrombi and the number of vessels
and thrombi per mm2 were calculated. To assess inflammatory involve-
ment, myocardial tissue was stained for MPO and CD45.18,19
2.5 Laboratory measurements performed
in the patient and porcine study
Laboratory measurements are described in detail in the Supplementary ma-
terial online. VWF factor activity (Innovance VWFAc) was determined on a
Behring Coagulation System according to protocols from the manufacturer
(Siemens Healthcare Diagnostics, Marburg, Germany). ADAMTS13 activity
was determined as described earlier.20 VWF antigen and VWF propeptide
levels were measured by ELISA using commercial antibodies (DAKO, Den-
mark and Sanquin, The Netherlands, respectively). Data are presented in
percentage activity or percentage of antigen. The reference value is derived
from normal pooled plasma. Our pool is composed of.200 healthy volun-
teers. D-dimer levels were determined with a particle-enhanced immuno-
turbidimetric assay (Innovance D-dimer, Siemens Healthcare Diagnostics).
Fibrinogen concentration was derived from the change in optical signal dur-
ing prothrombin time determination. Fibrinogen antigen was determined by
ELISA using antibodies fromDAKO (Glostrup, Denmark). The ability of rA-
DAMTS13 to cleave porcine VWF was determined in vitro by measuring
porcine VWF activity in plasma of animals before and after addition of
rADAMTS13.
2.6 Statistical analysis
Categorical data are presented as frequencies (percentage) and continuous
data as mean+ standard error (SE) or median with interquartile range
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(IQR). For the patient study, missing values for coagulation parameters at
specific time points were imputed using multiple imputation. The imput-
ation model included age, sex, and all coagulation parameters, and 20
data sets were created. Area under the receiver operator curve (AUC)
for levels of D-dimer, VWF activity, VWF antigen, VWF propeptide, and
ADAMTS13 was determined using blood measurements taken at T0, T1,
T4, and T7 (separately for each of the imputed data sets). Mean AUCs of
patients with and without IMH were compared using independent samples
t-tests. For comparisons of coagulation parameters at different time points,
repeated measures ANOVA was used with IMH/no IMH as a between-
factor and time point as a within-factor. To determine the correlation be-
tween continuous variables, Pearson’s R was calculated. Estimated mean
differences and P-values of the tests were pooled over the imputations
using the standard pooling procedures for multiple imputed data sets avail-
able in SPSS. For the porcine study, differences between treatment groups
were compared with Mann–Whitney U tests for unpaired and Wilcoxon
signed-rank tests for paired non-parametric analysis. Pearson’s x2 test
was performed on categorical variables, and ANOVA was used for regres-
sion. Plots of means were drawn using GraphPad Prism (GraphPad Soft-
ware 6.00, San Diego, CA, USA). Statistical analyses were performed
using SPSS software package (IBM SPSS Statistics 22.0, Chicago, IL, USA).
3. Results
3.1 General characteristics of the patient
study
Forty-nine STEMI patients underwent CMR between 4 and 6 days after
PCI. Clinical demographics and CMR parameters of these patients are
shown in Table 1.
3.2 IMH associated with higher VWF
activity and lower ADAMTS13 activity
CMR-defined IMH was found in 19 patients (39%). No significant inter-
action between the presence of IMH and time was found for VWF ac-
tivity, VWF antigen levels, ADAMSTS13 activity, and Fibrogen levels
(P ¼ 0.61, 0.83, 0.058, and 0.229, respectively), implying a similar differ-
ence between the mean levels of patients with and without IMH at all
time points. Mean VWF activity (Figure 1A ) and VWF antigen (Figure 1B)
levels were found to be consistently higher at all time points in patients
with IMH (mean difference IMH—no IMH+ SE; VWF activity: 35.8+
14.8, P ¼ 0.020, VWF antigen levels: 35.2+ 15.3, P ¼ 0.026). A signifi-
cant interaction between the presence of IMH and time was found for
VWF propeptide levels (P ¼ 0.008), with mean VWF propeptide levels
at T0 being significantly higher for patients with IMH, but not signifi-
cantly different at other time points (IMH vs. no IMH; mean+ SE,
P-value; T0: 335+ 16% vs. 249+ 13%, P, 0.001, T1: 127+ 16% vs.
93+ 13%, P ¼ 0.11, T4: 122+ 16% vs. 106+ 14%, P ¼ 0.45, T7:
109+ 18% vs. 117+ 14%, P ¼ 0.75) (Figure 1C). ADAMTS13 activity
was lower in patients with IMH (Figure 1D) (P ¼ 0.049). No difference
was found in fibrinogen (Figure 1E) levels between patients with and
without IMH (P ¼ 0.83). A significant interaction between the presence
of IMH and time was found for D-dimer levels (P ¼ 0.001), with mean
D-dimer levels at T0 and T1 being lower in IMH group and mean levels
at T4 and T7 being higher in IMH group but with post hoc tests for
comparison of mean levels between groups at T0, T1, T4 and T7 sep-
arately revealing no significant differences (IMH vs. no IMH; mean+ SE,
P-value; T0: 0.42+0.17 vs. 0.68+0.14, P ¼ 0.26, T1: 0.53+0.17 vs.
0.73+ 0.14, P ¼ 0.38, T4: 1.07+ 0.17 vs. 1.00+ 0.14, P ¼ 0.75, T7:
1.36+ 0.18 vs. 0.94+ 0.14, P ¼ 0.064) (Figure 1F).
3.3 No strong correlation between VWF
activity, ADAMTS13 activity, and infarct size
Mean infarct size [as percentage of the left ventricle (LV)] in STEMI pa-
tients was 17.5+ 12.3% and did not correlate substantially to
ADAMTS13 activity measured directly after PCI (R ¼ 20.162, P ¼
0.265) or to any other subsequent measurement (Figure 2A). VWF
activity correlated statistically significant with infarct size (Figure 2B),
but only at T4, and the correlation was weak (R ¼ 0.298, P ¼ 0.037).
Also, myocardial salvage did not correlate significantly to ADAMTS13
activity at T0 (R ¼ 0.032, P ¼ 0.831) or to measurements at other time
points. The same held true for the relationship between myocardial
salvage and VWF activity at T0 (R ¼ 20.159, P ¼ 0.285) as well as
T1, T4, and T7.
3.4 General characteristics of the porcine
study
In the present study, 23 animals were included (median age 83 days,
IQR 79–91; median weight 30 kg, IQR 27–34); 12 animals received
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Clinical demographics, angiographic












Smoking history 41 (84%)
Family history 33 (67%)




Infarct size (% of the LV) 17.5+12.3
Time to reperfusion (h) 2.6+1.3






Platelet glycoprotein IIb/IIIa inhibitors 14 (29%)
TIMI 3 flow grade post-PCI 46 (94%)
Incomplete (≤70%) ST-segment resolution
post-PCI
28 (57%)
Data are n or mean+ SD.
BMI, body mass index; CAD, coronary artery disease; CMR, cardiovascular magnetic
resonance; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVESV, left
ventricular end-systolic volume; LVEF, left ventricular ejection fraction; CK-MB,
creatine kinase-myocardial band; PCI, percutaneous coronary intervention.
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vehicle and 11 were given rADAMTS13. Two animals from the vehicle
arm died within 24 h after the intervention. In ex vivo experiments,
when adding increasing concentrations of rADAMTS13 to porcine
plasma, a corresponding decrease in VWF activity was measured.
In the porcine model, at T ¼ 75 min after reperfusion fibrinogen
(Figure 3A) decreased in comparison with baseline values. As all animals
received a substantial amount of intravenous fluids, albumin levels
(Figure 3B) at baseline and after release of the balloon were measured,
showing clear evidence of dilution (percentage decrease albumin at
T ¼ 75 min: 18%, P, 0.001, no differences between treatment
groups). This percentage was used to correct measurements of all
coagulation assays performed at T ¼ 75 min.
3.5 VWF and ADAMTS13 levels
in experimental myocardial
ischaemia-reperfusion
Median baseline VWF activity for all swine was 150% (IQR 127–172).
After correction for dilution, there was a trend towards increased
VWF activity directly following the intervention (median 165%, IQR
123–183, P ¼ 0.056). ADAMTS13 activity did not change after the
induced AMI (baseline vs. T ¼ 75 min: 18%, IQR 15–4 vs. 18%, IQR
16–24, P ¼ 0.57). Following intracoronary infusion of rADAMTS13
at 3 h after AMI, ADAMTS13 activity increased significantly to 324%
(IQR 117–384, P ¼ 0.003 in comparison with baseline, P, 0.001 vs.
Figure 1 VWF activity, VWF antigen, VWF propeptide, ADAMTS13 activity, and fibrinogen and D-dimer levels in STEMI patients treated with PCI.
(A) VWF activity (%), (B) VWF antigen (%), (C ) VWF propeptide (%), (D) ADAMTS13 activity (%), (E) fibrinogen level (g/L), and (F) D-dimer levels,
measured directly after PCI (T0) and at 1, 4, and 7 days following PCI (T1, T4, T7). VWF activity (P ¼ 0.021 for AUC) and VWF antigen levels
(P ¼ 0.020 for AUC) were significantly higher in patients with IMH compared with patients without IMH (n ¼ 19, 30 for IMH, no IMH/group). Mean
AUCs were compared using independent samples t-tests.
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control group that had a median level of 15%, IQR 11–19).
ADAMTS13 activity remained increased in the rADAMTS13-treated
group on all following measurements (P, 0.001 for repeated
measures ANOVA in comparison with control group). There was no
difference in VWF activity after infusion between both treatment
groups for all following measurements (P ¼ 0.99 for repeated mea-
sures ANOVA) (Figure 4E and F ).
Induction of myocardial infarction had no direct influence on fibrino-
gen levels (baseline vs. T ¼ 75 min: 3.3 g/L, IQR 3.0–3.5 vs. 3.3 g/L,
IQR 2.7–3.7; P ¼ 0.88). However, fibrinogen levels were increased at
1 and 7 days after induction of ischaemia-reperfusion (6.9, IQR 5.7–7.5
and 4.8, IQR 4.0–5.6, respectively; P, 0.001 vs. baseline for both)
compared with baseline levels. There were no differences in fibrinogen
measurements throughout the experiment between treated
animals and controls (P ¼ 0.80 for repeated measures ANOVA).
There were no differences in red blood cell count and platelet count
between rADAMTS13- and vehicle-treated animals throughout
the study (data not shown). In vitro studies proved the efficacy of
cleavage of porcine VWF by rADAMTS13 at a dosage of ,1 U/mL
(Figure 5).
3.6 No effects of rADAMTS13 on
ST-segment resolution, infarct size,
and cardiac function
ST-segment resolution and cardiac enzymes were similar between treat-
ment groups (see also Figure 6A and the Supplementary material online).
Microscopic infarct size as measured by PTAH staining was comparable
between rADAMTS13-treated group (6.7%, IQR 5.0–9.4) and control
group (8.2%, IQR 2.4–10.2; P ¼ 0.75, see also Figure 6B). Macroscopic
estimation of infarct size from photographed cross sections of the heart
showed no differences between rADAMTS13-treated animals and
controls (rADAMTS13 vs. controls: 25.1%, IQR 20.6–26.6 vs. 22.2%,
IQR 20.0–29.3; P¼ 0.97). rADAMTS13-treated animals had an in-
creased wall motion score index (WMSI) at 60 min after reperfusion
(P ¼ 0.009 for absolute values and P ¼ 0.02 for delta 2-1, see also
Supplementary material online, Table S1). No other differences were
observed between first and final echocardiogram for all echocardiog-
raphy parameters, when comparing rADAMTS13-treated animals
and controls (see also the echocardiographic analysis in the Supple-
mentary material online, Results and Table S1).
3.7 No effects of intracoronary
rADAMTS13 infusion on IMH or
formation of microthrombi
Histopathological findings showed that the core of all infarctions con-
tained haemorrhage. The size of IMH as a percentage of LV was similar
between treatment groups (rADAMTS13 vs. controls: 2.4%, IQR 1.2–
3.7 vs. 2.1%, IQR 0.8–4.8, P ¼ 0.97). Same results were found for IMH
as percentage of infarct size (rADAMTS13 vs. controls: 37.0%, IQR
27.3–43.7 vs. 30.1%, IQR 19.0–48.3, P ¼ 0.56) (Figure 3C).
The total number of microthrombi in the infarct tissue did not
differ between groups (rADAMTS13 vs. controls: 19.0 per section,
IQR 17.0–27.5 vs. 21.5 per section, IQR 17.5–28.5; P ¼ 0.65)
(Figure 3D).
Leukocytes as detected with CD45 and MPO staining were found
more often in the border zone (97.5, IQR 63.8–135.8) in comparison
with infarct tissue (17.8, IQR 11.1–28.9, P, 0.001) (Figure 3E). There
was no difference between rADAMTS13-treated and control animals
with regard to the presence of leukocytes in the infarcted tissue, the
border zone, or the non-affected myocardium.
4. Discussion
There is ample proof of the association between VWF/ADAMTS13
levels and myocardial infarction,12,13 and rADAMTS13 has been effect-
ive in reducing myocardial injury in rodent models.21 In the present
study, VWF/ADAMTS13 levels were assessed in 49 STEMI patients
and IMH was determined using CMR. Furthermore, rADAMTS13
was administered with the aim to limit myocardial injury in a porcine
myocardial ischaemia-reperfusion model. The main findings are the fol-
lowing: (i) IMH was associated with higher VWF activity and (eventual-
ly) lower ADAMTS13 activity; (ii) intracoronary administration of
rADAMTS13 did not reduce infarct size in a porcine myocardial ischae-
mia-reperfusion model on a background of dual antiplatelet therapy
and heparin.
Figure 2 Correlation between ADAMTS13 and VWF activity.
Mean infarct size (as percentage of the LV) in STEMI patients did
not correlate substantially to ADAMTS13. VWF levels correlated
statistically significant with infarct size.
E.S. Eerenberg et al.198
4.1 VWF and ADAMTS13 levels in patients
with IMH: cause or consequence?
STEMI patients with IMH had higher VWF activity immediately after PCI
and in all subsequent measurements. VWF propeptide, a cleavage
product of VWF, was significantly higher only in patients with IMH
for the first day. This could be explained by its short half-life of
2–3 h.22 Directly after PCI, there were no differences in ADAMTS13
activity between patients with and without IMH. Lower ADAMTS13
activity was found in patients with IMH at 4 and 7 days following STEMI.
These findings are in line with Zhao et al. who showed that VWF levels
in STEMI patients were higher immediately after PCI in patients with no
reflow, whereas ADAMTS13 levels did not differ between patients
with and without no reflow, until the seventh day after PCI.23
The present findings that VWF levels are increased in patients with
IMH and ADAMTS13 levels decreased are novel and counter-intuitive
at first. However, a similar pattern has been shown in patients after
hip surgery, and also patients with subarachnoid bleeding display in-
creased levels of VWF.24–26 VWF is believed to be an acute phase pro-
tein, and its levels increase in various inflammatory diseases.27 – 29
Possibly, the rise in VWF following AMI is an epiphenomenon or a neces-
sary compensation for IMH.
VWF and ADAMTS13 may nevertheless serve as diagnostic markers
to detect patients at risk of developing IMH. Especially, given that no re-
flow is detected angiographically in a minority of cases3 and that CMR,
although more effective in detecting no reflow,2,3 cannot be performed
directly in acute STEMI patients. Other frequently used markers of co-
agulation, D-dimer and fibrinogen, were similar in both patient groups.
4.2 No effect of rADAMTS13 in reducing
myocardial injury
Treatment with rADAMTS13 reduced infarct size in a murine stroke
model by 30% without signs of increased bleeding.30 Furthermore,
Figure 3 Fibrinogen and albumin levels, IMH, microthrombi, and leukocytes in the animal model. (A) Fibrinogen levels (T ¼ 75 min), (B) albumin levels
(T ¼ 0), (C) IMH in percentage of the LV and as percentage of infarct size (T ¼ 7), (D) number of microthrombi (T ¼ 7), and (E) number of leukocytes
(T ¼ 7) in rADAMTS13-treated animals compared with controls. n ¼ 11, 10 (rADAMTS13, control)/group.
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rADAMTS13 exerted antithrombotic effects in a model of vessel
damage in which ADAMTS13 decreased occlusion time of mesenteric
arterioles after FeCl3-induced thrombus formation.
31 In open chest
myocardial infarction models, a therapeutic benefit of rADAMTS13
was shown in both ADAMTS13 knockout mice and wild-type
mice treated with rADAMTS13.14 – 16 In all murine AMI studies,
rADAMTS13 led to a decrease in neutrophil accumulation in the in-
farcted myocardium. Interestingly, there was no evidence of any
antithrombotic effect of rADAMTS13. For instance, there was no re-
duction of thrombotic occlusions in myocardial microvessels. There-
fore, its therapeutic properties were deemed to be anti-inflammatory
rather than antithrombotic.14–16 The inflammatory response may have
been caused by the use of an open chest model, unlike the closed chest
approach in our study. Possibly, a beneficial effect of rADAMTS13 was
not found in our study due to the fact that the model used was not in-
flammatory or thrombotic enough. VWF activity did not increase
Figure 4 Study flow chart of the comprehensive study protocol, histopathological methods in the porcine ischaemia-reperfusion model, and
ADAMTS13 and VWF activity in the porcine ischaemia-reperfusion model. (A) Study flow chart. (B) Post-mortem sectioning of a porcine heart. (C )
Macroscopically visible infarcted area (indicated by # and *) was fixed and embedded. (D) PTAH staining, which stains non-haemorrhagic infarction
pink (1), haemorrhagic infarction dark purple (2), and viable tissue blue (3).44 (E) ADAMTS13 activity (%) measured before and after 75 min of balloon
occlusion (T ¼ 75 min) of the left circumflex artery (median and IQR). rADAMTS13-treated animals demonstrated elevated ADAMTS13 activity levels
compared with controls (P, 0.001). (F ) VWF activity (%) measured before and after 75 min of balloon occlusion (T ¼ 75 min) of the left circumflex
artery (median and IQR). rADAMTS13-treated animals had similar VWF activity levels compared with controls directly after reperfusion (T ¼ 75 min).
P ¼ 0.99 for rADAMTS13. n ¼ 11, 10 (rADAMTS13, control)/group. Mean AUCs were compared using independent samples t-tests.
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substantially after the infarction, and fibrinogen did not increase until
24 h. However, the model implemented in the present analysis has
been established and proved effective in detecting treatment effect in
myocardial injury models.32 – 36 Furthermore, the medical regime
used in our study was according to the ESC guidelines for STEMI
patients, mimicking the treatment of patients with AMI realistically. In
the rodent studies, no antiplatelet agent, heparin, or any other anti-
coagulant was applied besides rADAMTS13.14 – 16,37 Assessment of
area at risk would have attributed to a more standardized assessment
of ischaemia-reperfusion injury. However, assessment of area at risk
directly after the PCI was not possible, as the pigs would have to
have been killed immediately after the intervention.38 For the porcine
study, the choice was made to kill the swine 7 days after the interven-
tion, to better assess myocardial infarct size. All findings from this
study from several parameters (cardiac enzymes, continuous 12-lead
electrocardiograms, echocardiography, and histopathological analysis)
did point in the same direction, and this underlines the robustness of
the data.
In the rodent studies and the murine stroke model, rADAMTS13
was administered prior to reperfusion. In the present porcine myocar-
dial ischaemia-reperfusion model, rADAMTS13 was applied only
15 min following reperfusion. However, because rADAMTS13 primar-
ily works as an antagonist for VWF, it seems unlikely that its efficacy
would be less 15 min following reperfusion.11 Furthermore, patients
with AMI will likely be treated only with a therapeutic regime against
no reflow, following PCI.
4.3 High dosage, timing, and lack of efficacy
of rADAMTS13
ADAMTS13 levels increased.15-fold immediately after rADAMTS13
administration and remained elevated throughout the following 7 days.
It seems likely therefore that enough rADAMTS13 was applied. Fur-
thermore, in vitro studies proved the efficacy of cleavage of porcine
VWF by rADAMTS13 at a dosage of ,1 U/mL (see also Figure 5).
Pigs have an average circulating blood volume of 65 mL/kg body weight,
and pigs in the present study had a median weight of 30 kg, adding up to
a median circulating blood volume of 1950 mL. If 1 U/mL rADAMTS13
would be effective in vitro, 1950 U would be effective per pig. The
400 U/kg body weight rADAMTS13 dosage as applied, adding up to
a median of (400 × 30 kg) 12 000 U per pig should have to have
been sufficient. Perhaps an overdose of rADAMT13 may have caused
a potential direct effect on myocardial performance. Even though the
difference inWMSI was the only statistically significant finding, all echo-
cardiographic parameters showed a decrease between the first and the
second echocardiogram for the rADAMTS13 group, followed by a re-
covery from the second to the third (final) echocardiography (Supple-
mentary material online, Table S1). This may indicate a negative effect of
rADAMTS13 on cardiac function that would not have occurred with
lower dosages. However, treatment did not lead to an increased bleed-
ing tendency or increased IMH. Because the first minutes of reperfusion
are believed to be highly relevant for the development of
ischaemia-reperfusion injury, perhaps rADAMTS13 could have been
more effective when applied prior to the termination of the myocardial
infarction.
4.4 No reflow and IMH
An important finding in this study was provided by results from
anti-CD31 staining. Previously, it has been postulated that in no reflow,
distal embolization of atherosclerotic debris and local microthrombi
cause occlusion of capillaries.7 In contrast with this assumption, we
witnessed no microthrombi and very few microvessels in the core of
Figure 5 Cleavage of porcine VWF by rADAMTS13. In vitro studies
show that adding rADAMTS13 to porcine plasma results in a dose-
dependent decrease in VWF activity.
Figure 6 Results on infarct size from the porcine study. (A) Cardiac
enzyme troponin T (mg/L) was measured at 3, 6, and 24 h after the
balloon occlusion. Infarct size was calculated as the AUC of troponin
T.45 (B) Histopathological findings, using PTAH staining.44 Differences
between treatment groups were compared with Mann–Whitney
U tests for unpaired and Wilcoxon signed-rank tests for paired non-
parametric analysis.
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the infarction. Instead, obstruction of the microvasculature was more
evident in the border zone, whereas the core of the infarction
contained IMH. These results are in line with previous animal
studies,8–10,37,39–43 and recent reports suggesting that the pathophysi-
ology behind no reflow is IMH rather than microvascular obstruc-
tion.8–10 These insights in the pathophysiology behind no reflow may
explain why few therapeutic regimens have been effective in reducing
the morbidity and mortality caused by no reflow.2 This may also explain
why IMH size was similar in rADAMTS13-treated animals vs. controls
and why rADAMTS13 was not beneficial in the porcine study because
of the lack of a causal relationship betweenADAMTS13 levels and IMH.
4.5 Limitations
The exclusion of patients with TIMI 0–1 flow is possibly a limitation of
the present study. For the primary study in which this patient cohort
is reported,17 solely patients with TIMI 2 or 3 flow were included.
However, very few patients were actually excluded due to TIMI 0–1
flow (n ¼ 3).
In the porcine model, anaesthesia was maintained using sevoflurane,
an agent reported to have cardioprotective effects. Even though both
treatment groups were given the same anaesthesia, this may have
caused smaller infarct size in the total study group. MRI would have
been favourable to echocardiography. Unfortunately, due to logistic
reasons, it was not possible to perform MRI in all pigs.
We did not measure area at risk. Although total occlusion time and
anatomic site of occlusion were standardized, it cannot be excluded
that there were differences between the two groups in area at risk.
Also, we were not able to calculate total myocardial salvage in the
present study but only total infarct size. Potentially, administration of
rADAMTS13 prior to initiation of myocardial infarction does have a
beneficial effect. However, in clinical practice, this is not feasible and
therefore was not tested in the present pre-clinical study.
5. Conclusions
This is the first study to show that IMH as measured by CMR is asso-
ciated with increased VWF levels and decreased ADAMTS13 levels in
STEMI patients. Administration of rADAMTS13 was not effective in re-
ducing infarct size and no reflow in a porcine model of myocardial
ischaemia-reperfusion.
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